Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more
Paradigm Biopharmaceuticals Limited (PBIGF) - Net Assets
Latest net assets as of June 2025: $21.18 Million USD
Based on the latest financial reports, Paradigm Biopharmaceuticals Limited (PBIGF) has net assets worth $21.18 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.57 Million) and total liabilities ($3.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $21.18 Million |
| % of Total Assets | 86.21% |
| Annual Growth Rate | N/A |
| 5-Year Change | -72.94% |
| 10-Year Change | 88.64% |
| Growth Volatility | 154.5 |
Paradigm Biopharmaceuticals Limited - Net Assets Trend (2014–2025)
This chart illustrates how Paradigm Biopharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Paradigm Biopharmaceuticals Limited (2014–2025)
The table below shows the annual net assets of Paradigm Biopharmaceuticals Limited from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $21.18 Million | -11.01% |
| 2024-06-30 | $23.81 Million | -55.65% |
| 2023-06-30 | $53.68 Million | +26.86% |
| 2022-06-30 | $42.31 Million | -45.94% |
| 2021-06-30 | $78.27 Million | -27.65% |
| 2020-06-30 | $108.18 Million | +30.64% |
| 2019-06-30 | $82.81 Million | +497.27% |
| 2018-06-30 | $13.86 Million | +3.54% |
| 2017-06-30 | $13.39 Million | +19.23% |
| 2016-06-30 | $11.23 Million | -22.36% |
| 2015-06-30 | $14.46 Million | +9624.42% |
| 2014-06-30 | $-151.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Paradigm Biopharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23579711100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $253.23 Million | 1195.39% |
| Other Comprehensive Income | $3.90 Million | 18.41% |
| Total Equity | $21.18 Million | 100.00% |
Paradigm Biopharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Paradigm Biopharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
A Plus Asset Advisor Co Ltd
KO:244920
|
$97.37 Million |
|
Japan Display Inc
PINK:JNNDF
|
$97.39 Million |
|
Husteel
KO:005010
|
$97.43 Million |
|
HEXAOM S.A. EO -18
F:88M
|
$97.48 Million |
|
Dimand S.A.
AT:DIMAND
|
$97.35 Million |
|
Nexity SA
PINK:NNXXY
|
$97.33 Million |
|
Sunflag Iron And Steel Company Limited
NSE:SUNFLAG
|
$97.22 Million |
|
South Atlantic Bancshares Inc
OTCQX:SABK
|
$97.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paradigm Biopharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,806,097 to 21,184,037, a change of -2,622,060 (-11.0%).
- Net loss of 18,770,745 reduced equity.
- Other comprehensive income decreased equity by 2,522,127.
- Other factors increased equity by 18,670,812.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.77 Million | -88.61% |
| Other Comprehensive Income | $-2.52 Million | -11.91% |
| Other Changes | $18.67 Million | +88.14% |
| Total Change | $- | -11.01% |
Book Value vs Market Value Analysis
This analysis compares Paradigm Biopharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-06-30 | $-0.01 | $0.38 | x |
| 2015-06-30 | $0.44 | $0.38 | x |
| 2016-06-30 | $0.13 | $0.38 | x |
| 2017-06-30 | $0.13 | $0.38 | x |
| 2018-06-30 | $0.12 | $0.38 | x |
| 2019-06-30 | $0.58 | $0.38 | x |
| 2020-06-30 | $0.52 | $0.38 | x |
| 2021-06-30 | $0.37 | $0.38 | x |
| 2022-06-30 | $0.17 | $0.38 | x |
| 2023-06-30 | $0.19 | $0.38 | x |
| 2024-06-30 | $0.08 | $0.38 | x |
| 2025-06-30 | $0.07 | $0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paradigm Biopharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -36014.48%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-88.61%) is below the historical average (-59.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-215.81K |
| 2015 | -10.82% | 0.00% | 0.00x | 1.04x | $-3.01 Million |
| 2016 | -26.04% | -226.49% | 0.10x | 1.10x | $-4.05 Million |
| 2017 | -31.93% | -234.50% | 0.13x | 1.07x | $-5.61 Million |
| 2018 | -44.65% | -230.71% | 0.18x | 1.10x | $-7.58 Million |
| 2019 | -18.87% | -523.73% | 0.03x | 1.03x | $-23.91 Million |
| 2020 | -11.37% | 0.00% | 0.00x | 1.04x | $-23.12 Million |
| 2021 | -43.82% | -166895.38% | 0.00x | 1.08x | $-42.12 Million |
| 2022 | -92.76% | -49543.07% | 0.00x | 1.20x | $-43.48 Million |
| 2023 | -96.71% | -111013.71% | 0.00x | 1.25x | $-57.28 Million |
| 2024 | -246.38% | -89138.30% | 0.00x | 1.15x | $-61.03 Million |
| 2025 | -88.61% | -36014.48% | 0.00x | 1.16x | $-20.89 Million |
Industry Comparison
This section compares Paradigm Biopharmaceuticals Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paradigm Biopharmaceuticals Limited (PBIGF) | $21.18 Million | 0.00% | 0.16x | $97.36 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |